BACKGROUND: We examined several novel biomarkers of different pathophysiologic pathways as predictors of cardiovascular mortality in participants enrolled in the Minnesota Heart Survey (MHS), a population-based study of cardiovascular disease (CVD) risk factors. METHODS: In a nested case-control study within MHS, 7 biomarkers were assayed in serum samples from 211 patients identified after 8-15 years of follow-up who died of cardiovascular causes (cardiovascular heart disease, stroke, congestive heart failure) and 253 controls matched on age, sex, and study year. Logistic regression analysis, adjusted for age, race, sex, education, study year, smoking, abdominal obesity, diabetes, serum total cholesterol, systolic blood pressure, previous hospitalization for a CVD event, and other significant biomarkers, was used to evaluate the relations of biomarkers relative to the odds of CVD mortality. RESULTS: Cases survived a median of 7.2 years after enrollment. Increased N-terminal pro-B type natriuretic peptide (NT-proBNP) (19% vs 4.3%), increased high-sensitivity C-reactive protein (hs-CRP) (71% vs 51%), and increased high-sensitivity cardiac troponin I (hs-cTnI) (8.7% vs 1.0%) were more common among cases than among controls (all P < 0.001 in unadjusted analyses). The adjusted odds of death were greater among cases compared to controls for increased NT-proBNP [odds ratio (OR) 5.67, 95% CI 2.17-15], hs-CRP (OR 1.73, 95% CI 1.03-2.89), and hs-cTnI (OR 8.53, 95% CI 1.68-43), and decreased ST2 (OR 1.92, 95% CI 1.05-3.48). CONCLUSIONS: When measured by an hs-cTnI assay, cTnI is a key biomarker associated with increased cardiovascular death in a community sample when evaluated in a multiple biomarker analysis.
BACKGROUND: We examined several novel biomarkers of different pathophysiologic pathways as predictors of cardiovascular mortality in participants enrolled in the Minnesota Heart Survey (MHS), a population-based study of cardiovascular disease (CVD) risk factors. METHODS: In a nested case-control study within MHS, 7 biomarkers were assayed in serum samples from 211 patients identified after 8-15 years of follow-up who died of cardiovascular causes (cardiovascular heart disease, stroke, congestive heart failure) and 253 controls matched on age, sex, and study year. Logistic regression analysis, adjusted for age, race, sex, education, study year, smoking, abdominal obesity, diabetes, serum total cholesterol, systolic blood pressure, previous hospitalization for a CVD event, and other significant biomarkers, was used to evaluate the relations of biomarkers relative to the odds of CVD mortality. RESULTS: Cases survived a median of 7.2 years after enrollment. Increased N-terminal pro-B type natriuretic peptide (NT-proBNP) (19% vs 4.3%), increased high-sensitivity C-reactive protein (hs-CRP) (71% vs 51%), and increased high-sensitivity cardiac troponin I (hs-cTnI) (8.7% vs 1.0%) were more common among cases than among controls (all P < 0.001 in unadjusted analyses). The adjusted odds of death were greater among cases compared to controls for increased NT-proBNP [odds ratio (OR) 5.67, 95% CI 2.17-15], hs-CRP (OR 1.73, 95% CI 1.03-2.89), and hs-cTnI (OR 8.53, 95% CI 1.68-43), and decreased ST2 (OR 1.92, 95% CI 1.05-3.48). CONCLUSIONS: When measured by an hs-cTnI assay, cTnI is a key biomarker associated with increased cardiovascular death in a community sample when evaluated in a multiple biomarker analysis.
Authors: Christopher R deFilippi; James A de Lemos; Robert H Christenson; John S Gottdiener; Willem J Kop; Min Zhan; Stephen L Seliger Journal: JAMA Date: 2010-11-15 Impact factor: 56.272
Authors: Russell V Luepker; Donna K Arnett; David R Jacobs; Susan J Duval; Aaron R Folsom; Christopher Armstrong; Henry Blackburn Journal: Am J Med Date: 2006-01 Impact factor: 4.965
Authors: Till Keller; Stergios Tzikas; Tanja Zeller; Ewa Czyz; Lars Lillpopp; Francisco M Ojeda; Alexander Roth; Christoph Bickel; Stephan Baldus; Christoph R Sinning; Philipp S Wild; Edith Lubos; Dirk Peetz; Jan Kunde; Oliver Hartmann; Andreas Bergmann; Felix Post; Karl J Lackner; Sabine Genth-Zotz; Viviane Nicaud; Laurence Tiret; Thomas F Münzel; Stefan Blankenberg Journal: J Am Coll Cardiol Date: 2010-05-11 Impact factor: 24.094
Authors: James A de Lemos; Mark H Drazner; Torbjorn Omland; Colby R Ayers; Amit Khera; Anand Rohatgi; Ibrahim Hashim; Jarett D Berry; Sandeep R Das; David A Morrow; Darren K McGuire Journal: JAMA Date: 2010-12-08 Impact factor: 56.272
Authors: James L Januzzi; Carlos A Camargo; Saif Anwaruddin; Aaron L Baggish; Annabel A Chen; Daniel G Krauser; Roderick Tung; Renee Cameron; J Tobias Nagurney; Claudia U Chae; Donald M Lloyd-Jones; David F Brown; Stacy Foran-Melanson; Patrick M Sluss; Elizabeth Lee-Lewandrowski; Kent B Lewandrowski Journal: Am J Cardiol Date: 2005-04-15 Impact factor: 2.778
Authors: Alfons Gegenhuber; Joachim Struck; Werner Poelz; Richard Pacher; Nils G Morgenthaler; Andreas Bergmann; Meinhard Haltmayer; Thomas Mueller Journal: Clin Chem Date: 2006-03-16 Impact factor: 8.327
Authors: Daiana Stolz; Mirjam Christ-Crain; Nils G Morgenthaler; Jörg Leuppi; David Miedinger; Roland Bingisser; Christian Müller; Joachim Struck; Beat Müller; Michael Tamm Journal: Chest Date: 2007-04 Impact factor: 9.410
Authors: Bernhard M Kaess; Tonia de Las Heras Gala; Astrid Zierer; Christa Meisinger; Simone Wahl; Annette Peters; John Todd; Christian Herder; Cornelia Huth; Barbara Thorand; Wolfgang Koenig Journal: Eur J Epidemiol Date: 2017-06-05 Impact factor: 8.082
Authors: Nilson T Poppi; Luís H W Gowdak; Luciana O C Dourado; Eduardo L Adam; Thiago N P Leite; Bruno M Mioto; José E Krieger; Luiz A M César; Alexandre C Pereira Journal: Clin Cardiol Date: 2016-10-18 Impact factor: 2.882
Authors: Mary Emma Gorham Bigelow; Brian G Jamieson; Chi On Chui; Yufei Mao; Kyeong-Sik Shin; Tony Jun Huang; Po-Hsun Huang; Liqiang Ren; Bishow Adhikari; Jue Chen; Erin Iturriaga Journal: IEEE J Transl Eng Health Med Date: 2016-07-22 Impact factor: 3.316